EVIDENCE OF THE SELECTIVE ALTERATION OF ANTHRACYCLINE ACTIVITY DUE TO MODULATION BY ICRF-187 (ADR-529)

被引：27

作者：

GREEN, MD

ALDERTON, P

GROSS, J

MUGGIA, FM

SPEYER, JL

机构：

[1] UNIV SO CALIF, NORRIS CANC CTR, LOS ANGELES, CA 90033 USA

[2] NYU, DIV ONCOL, NEW YORK, NY 10016 USA

[3] UNIV MELBOURNE, ROYAL MELBOURNE HOSP, DEPT PATHOL, MELBOURNE, VIC 3050, AUSTRALIA

来源：

PHARMACOLOGY & THERAPEUTICS | 1990年 / 48卷 / 01期

关键词：

D O I：

10.1016/0163-7258(90)90018-W

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Anthracyclines are powerful anticancer drugs whose use is limited by the development of chronic cardiotoxicity. The bisdioxopiperazine compound ICRF-187 (ADR-529) specifically abrogates this toxicity both in preclinical animal models and in humans. It does this without effecting either the acute toxicities or the anticancer activity. Therefore, with a specific antagonist, the mechanism of activity of the anthracyclines can be explored. This review discusses recent clinical trials and animal models addressing this issue and concludes by hypothesizing a mechanism of action. © 1990.

引用

页码：61 / 69

页数：9

共 77 条

[1]

ADACHI T, 1983, J PHARMACOBIO-DYNAM, V6, P114

[2] IRON(III) ADRIAMYCIN AND IRON(III) DAUNORUBICIN COMPLEXES - PHYSICOCHEMICAL CHARACTERISTICS, INTERACTION WITH DNA, AND ANTITUMOR-ACTIVITY [J].